This model, performed in male C57 mice, resulted in chronic hypertension, moderate cardiac hypertrophy and dysfunction, and rarefaction of cardiac lymphatics, which all were improved by VEGF-CC156S therapy. This evidence concerns the gene VEGFA and cardiac hypertrophy.